- Home
- OTLK vs ONCY Comparison
OTLK vs ONCY Comparison
Compare OTLK & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- ONCY
- Stock Information
- Founded
- OTLK 2010
- ONCY 1998
- Country
- OTLK United States
- ONCY Canada
- Employees
- OTLK N/A
- ONCY N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- ONCY Pharmaceuticals and Biotechnology
- Sector
- OTLK Health Care
- ONCY Health Care
- Exchange
- OTLK Nasdaq
- ONCY Nasdaq
- Market Cap
- OTLK 56.3M
- ONCY 56.2M
- IPO Year
- OTLK 2016
- ONCY 1999
- Fundamental
- Price
- OTLK $1.48
- ONCY $0.62
- Analyst Decision
- OTLK Strong Buy
- ONCY Strong Buy
- Analyst Count
- OTLK 5
- ONCY 4
- Target Price
- OTLK $10.20
- ONCY $4.00
- AVG Volume (30 Days)
- OTLK 479.6K
- ONCY 319.2K
- Earning Date
- OTLK 02-14-2025
- ONCY 03-07-2025
- Dividend Yield
- OTLK N/A
- ONCY N/A
- EPS Growth
- OTLK N/A
- ONCY N/A
- EPS
- OTLK N/A
- ONCY N/A
- Revenue
- OTLK N/A
- ONCY N/A
- Revenue This Year
- OTLK N/A
- ONCY N/A
- Revenue Next Year
- OTLK $288.46
- ONCY $886.30
- P/E Ratio
- OTLK N/A
- ONCY N/A
- Revenue Growth
- OTLK N/A
- ONCY N/A
- 52 Week Low
- OTLK $0.87
- ONCY $0.58
- 52 Week High
- OTLK $12.85
- ONCY $1.53
- Technical
- Relative Strength Index (RSI)
- OTLK 40.05
- ONCY 35.98
- Support Level
- OTLK $1.38
- ONCY $0.58
- Resistance Level
- OTLK $1.51
- ONCY $0.76
- Average True Range (ATR)
- OTLK 0.12
- ONCY 0.05
- MACD
- OTLK 0.02
- ONCY -0.01
- Stochastic Oscillator
- OTLK 38.86
- ONCY 21.39
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatment. The other projects in the company's pipeline include, Bracelet-1 for treatment of Breast Cancer, Goblet cohort-1, Goblet cohort-5 for treatment of Gastro-Intestinal Cancer among others.